Philippe L. Bedard, MD

This video examines the use of molecular diagnostics for guiding adjuvant endocrine therapy in patients with breast cancer.

As Calabrich and colleagues illustrate in their comprehensive review in this issue of ONCOLOGY, there is a seemingly endless array of mechanisms by which the HER2-positive breast cancer cell can escape the control of trastuzumab (Herceptin).